कृपया अन्य खोज का प्रयास करें
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Dennis Arthur Ausiello | 75 | 2018 | Independent Director |
Andrew Farquharson | 52 | 2012 | Director |
Mir A. Imran | 65 | 2021 | Executive Chairman |
Maulik Nanavaty | 59 | 2016 | Independent Director |
Lisa Ann Rometty | - | 2022 | Non-Employee Director |
Lisa Ann Rometty | 55 | 2022 | Independent Director |
Jean-Luc Butel | 67 | 2021 | Independent Director |
Laureen DeBuono | 65 | 2021 | Lead Independent Director |
Talat Imran | 41 | 2021 | CEO & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है